Clifford Swan Investment Counsel’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.16M Buy
76,120
+400
+0.5% +$46.2K 0.31% 87
2025
Q4
$7.97M Sell
75,720
-951
-1% -$89.3K 0.26% 97
2025
Q3
$6.44M Sell
76,671
-2,123
-3% -$175K 0.21% 100
2025
Q2
$6.24M Sell
78,794
-2,872
-4% -$228K 0.22% 101
2025
Q1
$7.33M Sell
81,666
-650
-0.8% -$60.7K 0.27% 91
2024
Q4
$8.19M Sell
82,316
-1,671
-2% -$172K 0.29% 86
2024
Q3
$9.54M Buy
83,987
+4,050
+5% +$481K 0.34% 79
2024
Q2
$9.9M Buy
79,937
+438
+0.6% +$56.4K 0.37% 75
2024
Q1
$10.5M Sell
79,499
-3,712
-4% -$458K 0.39% 72
2023
Q4
$9.07M Buy
83,211
+136
+0.2% +$14.1K 0.35% 79
2023
Q3
$8.55M Sell
83,075
-876
-1% -$94.4K 0.36% 81
2023
Q2
$9.69M Sell
83,951
-550
-0.7% -$62.4K 0.39% 76
2023
Q1
$8.99M Sell
84,501
-21
-0% -$2.27K 0.38% 77
2022
Q4
$9.38M Sell
84,522
-731
-0.9% -$74.7K 0.41% 74
2022
Q3
$7.34M Hold
85,253
0.34% 81
2022
Q2
$7.77M Buy
85,253
+378
+0.4% +$33.5K 0.34% 86
2022
Q1
$6.96M Sell
84,875
-422
-0.5% -$33.3K 0.26% 100
2021
Q4
$6.54M Sell
85,297
-474
-0.6% -$37.8K 0.23% 104
2021
Q3
$7.53M Buy
85,771
+100
+0.1% +$7.61K 0.28% 97
2021
Q2
$6.47M Sell
85,671
-4,427
-5% -$329K 0.25% 100
2021
Q1
$6.63M Buy
90,098
+95
+0.1% +$7.01K 0.27% 95
2020
Q4
$7.03M Sell
90,003
-2,409
-3% -$184K 0.31% 87
2020
Q3
$7.31M Sell
92,412
-1,411
-2% -$111K 0.35% 80
2020
Q2
$6.92M Sell
93,823
-10
-0% -$753 0.36% 81
2020
Q1
$6.89M Sell
93,833
-188
-0.2% -$14.8K 0.42% 75
2019
Q4
$8.16M Sell
94,021
-800
-0.8% -$65.7K 0.39% 79
2019
Q3
$7.62M Buy
94,821
+488
+0.5% +$39.1K 0.4% 78
2019
Q2
$7.55M Sell
94,333
-669
-0.7% -$51.2K 0.4% 79
2019
Q1
$7.54M Sell
95,002
-524
-0.5% -$39.2K 0.4% 78
2018
Q4
$6.96M Sell
95,526
-1,101
-1% -$77.7K 0.42% 74
2018
Q3
$6.54M Sell
96,627
-1,542
-2% -$98.2K 0.34% 86
2018
Q2
$5.69M Buy
98,169
+160
+0.2% +$9.03K 0.32% 87
2018
Q1
$5.09M Sell
98,009
-838
-0.8% -$45.3K 0.29% 95
2017
Q4
$5.31M Buy
98,847
+28,866
+41% +$1.6M 0.29% 98
2017
Q3
$4.28M Buy
69,981
+353
+0.5% +$21.4K 0.26% 97
2017
Q2
$4.26M Sell
69,628
-2,306
-3% -$140K 0.27% 95
2017
Q1
$4.36M Sell
71,934
-9,369
-12% -$568K 0.28% 92
2016
Q4
$4.57M Sell
81,303
-367
-0.4% -$21.5K 0.31% 84
2016
Q3
$4.86M Buy
81,670
+105
+0.1% +$6.14K 0.33% 82
2016
Q2
$4.48M Sell
81,565
-3,934
-5% -$209K 0.31% 80
2016
Q1
$4.32M Sell
85,499
-14,569
-15% -$714K 0.29% 83
2015
Q4
$5.04M Sell
100,068
-1,936
-2% -$97.6K 0.35% 75
2015
Q3
$4.81M Sell
102,004
-2,360
-2% -$125K 0.34% 75
2015
Q2
$5.67M Sell
104,364
-312
-0.3% -$17.5K 0.38% 69
2015
Q1
$5.74M Buy
104,676
+1,663
+2% +$94.2K 0.38% 69
2014
Q4
$5.58M Sell
103,013
-523
-0.5% -$29.1K 0.37% 67
2014
Q3
$5.86M Sell
103,536
-668
-0.6% -$37.5K 0.4% 67
2014
Q2
$5.75M Sell
104,204
-1,907
-2% -$104K 0.39% 71
2014
Q1
$5.75M Buy
106,111
+4,976
+5% +$258K 0.4% 68
2013
Q4
$4.83M Buy
101,135
+1,845
+2% +$84.3K 0.35% 73
2013
Q3
$4.51M Buy
99,290
+1,101
+1% +$50.3K 0.36% 72
2013
Q2
$4.35M Buy
+98,189
New +$4.39M 0.36% 72

Other funds holding MRK

Clifford Swan Investment Counsel's MRK Position: Q1 2026 in Review

Clifford Swan Investment Counsel increased its Merck (MRK) stake by 0.53% in Q1 2026, buying an estimated $46.2K and bringing the position to 76,120 shares worth $9.16M. The position accounts for 0.31% of the portfolio, ranked #87.

Clifford Swan Investment Counsel first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.5M in Q1 2024. 3,788 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Clifford Swan Investment Counsel held 76,120 shares of Merck worth $9.16M as of Q1 2026.
  • Clifford Swan Investment Counsel bought 400 Merck shares in Q1 2026, an estimated $46.2K.
  • Merck made up 0.31% of Clifford Swan Investment Counsel's portfolio in Q1 2026, its #87 holding.
  • Clifford Swan Investment Counsel first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Clifford Swan Investment Counsel's Merck position peaked at $10.5M in Q1 2024.
  • 3,788 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Clifford Swan Investment Counsel's 13F filing for Q1 2026, filed 6 May 2026.